Dr. Martens Plc (GB:DOCS)
LSE:DOCS
DOCS Stock Chart & Stats
62.90 p
-1.05 p(-1.49%)
At close: 4:00 PM EST
62.90 p
-1.05 p(-1.49%)
Day’s Range― - ―
52-Week Range46.10 p - 100.87 p
Previous CloseN/A
Volume189.83K
Average Volume (3M)1.82M
Market Cap
£608.08M
Enterprise Value909.40M
Total Cash (Recent Filing)£95.70M
Total Debt (Recent Filing)£397.10M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
May 28, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend Yield3.36%
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding967,472,960
10 Day Avg. Volume1,078,739
30 Day Avg. Volume1,820,978
Financial Highlights & Ratios
PEG Ratio-1.17
Price to Book (P/B)1.34
Price to Sales (P/S)0.62
P/FCF Ratio2.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£93.75Price Target Upside49.05% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)0.05
Revenue Forecast (FY)£815.42M
Bulls Say, Bears Say
Bulls Say
DTC Margin / Brand StrengthGrowth in full-price DTC sales and more new full-price buyers indicates stronger brand pull and improved revenue quality. Higher DTC mix preserves retail margin versus wholesale, supporting more durable gross margins and better cash conversion over multiple quarters.
High Gross Margin And Strong FCFA ~65% gross margin provides structural pricing power in footwear. Coupled with rising free cash flow, this supports reinvestment, store/DTC expansion, and debt reduction without reliance on equity raises, improving long-term resilience through industry cycles.
Improving Leverage And Balance SheetMaterial year-on-year debt reduction and manageable leverage metrics increase financial flexibility. Lower net debt reduces refinancing risk and interest burden, allowing the company to fund strategic initiatives and withstand demand volatility over the medium term.
Bears Say
Declining Revenue And Low Net MarginSustained negative revenue growth and a collapse in net margin signal weakening top-line momentum and limited operating leverage. Persistent low profitability constrains cash available for growth, marketing, and product development, risk eroding competitive position if not reversed.
Collapsed Returns On EquityA sharp ROE decline reflects deteriorating capital efficiency and reduced shareholder returns. If capital is not redeployed into higher-return initiatives, investor economics remain weak and the company may struggle to justify capital allocation priorities over the next several quarters.
Regional/product Mix Pressures & TariffsWeakness in EMEA DTC and core product segments shows structural demand and assortment issues in key markets. Combined with tariff-driven cost headwinds, this can depress margins and force higher markdowns or investment in product redesign, challenging sustainable margin recovery.
Dr. Martens Plc News
DOCS FAQ
What was Dr. Martens Plc’s price range in the past 12 months?
Dr. Martens Plc lowest share price was 46.10 p and its highest was 100.87 p in the past 12 months.
What is Dr. Martens Plc’s market cap?
Dr. Martens Plc’s market cap is £608.08M.
When is Dr. Martens Plc’s upcoming earnings report date?
Dr. Martens Plc’s upcoming earnings report date is May 28, 2026 which is in 50 days.
How were Dr. Martens Plc’s earnings last quarter?
Dr. Martens Plc released its earnings results on Nov 20, 2025. The company reported -0.009 p earnings per share for the quarter, the consensus estimate of -0.009 p by 0 p.
Is Dr. Martens Plc overvalued?
According to Wall Street analysts Dr. Martens Plc’s price is currently Undervalued.
Does Dr. Martens Plc pay dividends?
Dr. Martens Plc pays a Semiannually dividend of 0.85 p which represents an annual dividend yield of 3.36%. See more information on Dr. Martens Plc dividends here
What is Dr. Martens Plc’s EPS estimate?
Dr. Martens Plc’s EPS estimate is 0.05.
How many shares outstanding does Dr. Martens Plc have?
Dr. Martens Plc has 967,472,960 shares outstanding.
What happened to Dr. Martens Plc’s price movement after its last earnings report?
Dr. Martens Plc reported an EPS of -0.009 p in its last earnings report, expectations of -0.009 p. Following the earnings report the stock price went down -9.558%.
Which hedge fund is a major shareholder of Dr. Martens Plc?
Currently, no hedge funds are holding shares in GB:DOCS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dr. Martens Plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
£93.75 (49.05% Upside)
£93.75 (49.05% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.81%
12-Months-Change
Fundamentals
Return on Equity
4.40%
Trailing 12-Months
Asset Growth
-7.19%
Trailing 12-Months
Company Description
Dr. Martens Plc
Dr. Martens plc designs, develops, procures, markets, sells, and distributes footwear in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. Its product segments include originals, fusion, kids, and casual, as well as accessories. The company offers its products under the Dr. Martens brand name. Dr. Martens plc was founded in 1945 and is based in London, the United Kingdom.
DOCS Stock 12 Month Forecast
Average Price Target
93.75 p
▲(49.05% Upside)
Technical Analysis
Options Prices
Currently, No data available
---